Previous Statements by NKTR
» Nektar CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Nektar Therapeutics Q2 2010 Earnings Call Transcript
» Nektar Therapeutics Q1 2010 Earnings Call Transcript
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.
The big issue is if the market can build on Friday's jobs good news.